通策醫療股票討論區

Topchoice Medical's declining ROCE trend and stagnant sales growth do not bode well for its potential as a multi-bagger stock. Despite reinvestment efforts, returns remain unimpressive, hinting at better investment opportunities elsewhere.

Topchoice Medical's share price drop doesn't align with its EPS and revenue growth, hinting at other influencing factors. The company's past over-hyped growth and a 16% broader market decline may have impacted the stock's performance.

Despite a decline in Topchoice Medical's ROCE and increasing capital usage, its stock has risen by 79% in the past five years. If these trends persist, its potential as a multi-bagger stock seems low.

Topchoice Medical could still be a good pick for long-term investors, given its steady EPS growth and 5-year return of 14% annually. The recent share price dip may offer a buying opportunity if long-term growth signs are evident.